Obesity journal asks whether multi-dose tirzepatide pens will drive microdosing

A commentary published in the journal Obesity, titled "Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens," argues that the arrival of multi-dose tirzepatide pen devices removes a physical barrier that once made it harder for patients to split doses on their own ^[1]. The authors say this turns a mostly academic question about off-label "microdosing" into something more urgent, because the tool for doing it is now in more people's hands ^[1].

The argument follows a similar one made about semaglutide pens in Diabetes Care in early 2025. In that piece, pharmacists and physicians at the University of North Carolina described how semaglutide multidose pens deliver medication in roughly 72 unnumbered "clicks," with no dial markings to show an exact dose, meaning patients who want a smaller-than-labeled amount must count clicks themselves using guidance from a provider ^[2]. The same pens have a beyond-use date of 56 days at room temperature or in the refrigerator, and each original package includes only four to six pen needles, so the authors recommended stocking additional 32-gauge needles for patients doing this regularly ^[2].

That 2025 paper listed several reasons patients or clinicians might turn to microdosing: easing severe gastrointestinal side effects by increasing more gradually, adjusting doses up or down without a new prescription, transitioning between different GLP-1 drugs, and stretching a single pen further for people paying out of pocket ^[2]. It also noted that supply shortages have pushed some patients toward unregulated, compounded versions of these drugs, and argued that microdosing an FDA-approved product might be a safer alternative to that route ^[2]. The same commentary pointed out that tirzepatide vials were already being used this way before multi-dose pens existed ^[2].

A companion piece on the tirzepatide question appeared in the same journal, Obesity, in August 2026, according to the development being reported here, but the specific arguments or findings in that follow-up are not detailed in the sources available for this story, so what it adds is not yet known.

Why it matters for patients

Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, and semaglutide, sold as Ozempic, Wegovy, and Rybelsus, are all approved and labeled for specific, fixed doses. Multi-dose pens were designed to let one device deliver several scheduled doses over time, not to let patients pick their own fractional amount ^[1][2]. When a pen has no numbered dial, counting clicks to estimate a smaller dose depends on the patient's technique and the guidance they receive, which creates room for error ^[2].

There is currently no dedicated clinical trial data cited in these papers showing how microdosed amounts compare with FDA-approved doses in terms of effectiveness or side effects. The 2025 semaglutide commentary framed microdosing as a practical workaround for real problems, cost, shortages, and side effects, rather than a proven treatment strategy ^[2]. The new tirzepatide commentary raises the same concern for a different drug, arguing that because the physical pen now makes splitting doses easier, more patients may attempt it without formal guidance, even though the evidence base has not caught up ^[1].

What happens next

The companion piece in Obesity appeared in August 2026, but its content is not available in the sources reviewed for this story ^[1]. It is not yet known whether drug manufacturers or the Food and Drug Administration will issue specific guidance on microdosing multi-dose tirzepatide or semaglutide pens, or whether more formal studies of fractional dosing are planned, based on the sources available here.